<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Phosphoglycerate kinase deficiency and phosphoglycerate mutase deficiency</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Phosphoglycerate kinase deficiency and phosphoglycerate mutase deficiency</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Phosphoglycerate kinase deficiency and phosphoglycerate mutase deficiency</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Basil T Darras, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William J Craigen, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sihoun Hahn, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth TePas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 30, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Glycogen is the stored form of glucose and serves as a buffer for glucose needs. It is composed of long polymers of a 1-4 linked glucose, interrupted by a 1-6 linked branch point every 4 to 10 residues. Glycogen is formed in periods of dietary carbohydrate loading and broken down when glucose demand is high or dietary availability is low  (<a class="graphic graphic_figure graphicRef81164" href="/d/graphic/81164.html" rel="external">figure 1</a>).</p><p>There are a number of inborn errors of glycogen metabolism that result from mutations in genes for virtually all of the proteins involved in glycogen synthesis, degradation, or regulation. Those disorders that result in abnormal storage of glycogen are known as glycogen storage diseases (GSDs)  (<a class="graphic graphic_table graphicRef54417" href="/d/graphic/54417.html" rel="external">table 1</a>).</p><p>Glycogen is most abundant in liver and muscle. The major manifestations of disorders of glycogen metabolism affecting the liver are hypoglycemia and hepatomegaly, and the primary features of those defects that affect muscle are muscle cramps, exercise intolerance, easy fatigability, and progressive weakness.</p><p>This topic will review phosphoglycerate kinase (PGK) deficiency and phosphoglycerate mutase (PGAM) deficiency (GSD X). An overview of disorders of glycogen metabolism is presented separately. (See  <a class="medical medical_review" href="/d/html/2941.html" rel="external">"Overview of inherited disorders of glucose and glycogen metabolism"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PHOSPHOGLYCERATE KINASE DEFICIENCY</span><span class="headingEndMark"> — </span>PGK catalyzes the conversion of 1,3-diphosphoglycerate to 3-phosphoglycerate. One molecule of adenosine triphosphate (ATP) is generated in the process. Deficiency of PGK (MIM #311800) results in three different clinical presentations. (See <a class="local">'Clinical features'</a> below.)</p><p class="headingAnchor" id="H3"><span class="h2">Genetics</span><span class="headingEndMark"> — </span>PGK1 is a monomeric enzyme encoded by a gene on chromosome Xq13 (<em>PGK1</em>). Thus, inheritance occurs as an X-linked recessive trait [<a href="#rid1">1</a>]. An isoform (PGK2) is expressed in spermatogenic cells. A variety of missense and nonsense variants of <em>PGK1</em> have been described [<a href="#rid2">2</a>]. No clear genotype-phenotype association has been identified, except that there appears to be clustering of all myopathic variants in the C-terminal domain near the substrate-binding pocket [<a href="#rid3">3</a>]. Another study, however, indicated that the different clinical manifestations associated with PGK1 deficiency chiefly depend upon the distinctive type of perturbations caused by pathogenic variants in the <em>PGK1</em> gene, highlighting the need for determination of the molecular properties of PGK variants to assist in prognosis and genetic counseling [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Clinical features</span><span class="headingEndMark"> — </span>The age of onset for PGK deficiency is variable. PGK deficiency may present as either isolated or associated involvement of three tissues (erythrocytes, the central nervous system [CNS], and skeletal muscle). The amount of residual enzyme activity appears to modulate the phenotype [<a href="#rid5">5-9</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>CNS involvement</strong> – CNS dysfunction with seizures and intellectual disability that is associated with nonspherocytic hemolytic anemia. The PGK-Barcelona pathogenic variant (a c.140T&gt;A, p.I47N) results in loss of enzyme stability and causes progressive neurologic impairment with associated chronic hemolytic anemia [<a href="#rid10">10</a>]. Patients with hemolytic anemia and CNS involvement usually lack evidence of clinical myopathy [<a href="#rid11">11-14</a>]. However, recurrent myoglobinuria was reported in a 33-year-old man with intellectual disability and reduced PGK1 activity in his muscles and erythrocytes [<a href="#rid15">15</a>]. Also, progressive leukodystrophy was described in a male patient with a history of congenital hemolytic anemia, rhabdomyolysis, and intellectual disability [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1"><strong>or</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Erythrocyte involvement</strong> – Hereditary nonspherocytic hemolytic anemia without CNS involvement [<a href="#rid8">8</a>]. Heterozygous females may have variable degrees of enzyme activity and may show some signs of hemolytic anemia.</p><p></p><p class="bulletIndent1"><strong>or</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Skeletal muscle involvement</strong> – Isolated myopathy with exercise intolerance, myoglobinuria, cramps, and slowly progressive weakness. Patients with myoglobinuria usually do not develop hemolytic anemia [<a href="#rid3">3,17</a>], but concurrent hemolysis and rhabdomyolysis with associated hemoglobinuria and myoglobinuria may occur (PGK-Osaka; p.S62N) [<a href="#rid18">18</a>], and, in two cases, all three clinical features were described (p.A354P and p.I371K) [<a href="#rid19">19,20</a>]. In addition, exertional myoglobinuria and severe parkinsonism, but no hemolytic anemia, was reported in a 25-year-old man with the p.T378P variant [<a href="#rid21">21</a>]. A second, unrelated patient with presumed isolated myopathy and the same <em>PGK1</em> variant also developed parkinsonism a year later [<a href="#rid22">22</a>]. Parkinsonism was also reported in a 36-year-old female carrier of a <em>PGK1</em> gene pathogenic variant, suggesting that <em>PGK1</em> mutations may confer susceptibility to parkinsonism. Her affected son had developed parkinsonism at nine years of age [<a href="#rid23">23</a>]. In a study of three patients with early-onset parkinsonism, 99mTc-TRODAT-1 SPECT, a dopamine transporter-specific tropane derivative, showed severe bilateral reduced putaminal uptake in the absence of structural changes, implicating the glycolytic pathway in nigrostriatal pathology [<a href="#rid24">24</a>]. Only nine cases of isolated myopathy have been reported thus far [<a href="#rid3">3</a>], but patients with PGK deficiency need to be followed for a number of years before concluding that they have only a myopathy [<a href="#rid25">25</a>]. In patients with myopathy, the resting serum creatine kinase (CK) level is usually elevated, although this feature is not uniformly observed. Muscle biopsy may reveal glycogen accumulation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Involvement of all three tissues</strong> – A novel <em>PGK1</em> mutation (PKG1 Galveston, c.472 G&gt;C) was reported in a four-year-old boy who presented with all three clinical manifestations [<a href="#rid26">26</a>].</p><p></p><p class="headingAnchor" id="H1478332"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis is made by demonstrating a deficiency of PGK1 enzymatic activity in muscle biopsy tissue and/or erythrocytes or by molecular analysis of the <em>PGK1</em> gene [<a href="#rid27">27</a>]. There may be a history of known or suspected PGK deficiency in relatives (following an X-linked inheritance pattern). Laboratories that provide this testing are listed separately. (See  <a class="medical medical_review" href="/d/html/7128.html" rel="external">"Rare RBC enzyme disorders", section on 'Phosphoglycerate kinase (PGK) deficiency'</a>.)</p><p>Increased tetraglucoside excretion was documented in the urine of patients with PGK1 deficiency [<a href="#rid28">28</a>]. The authors have proposed measurement of urine tetraglucoside excretion as a screening test for possible glycogenosis.</p><p>The myopathic form typically presents in childhood and is difficult to distinguish clinically from glycogen storage disease (GSD) V (muscle phosphorylase deficiency) and GSD VII (muscle phosphofructokinase deficiency) without muscle biopsy and biochemical determinations [<a href="#rid29">29</a>]. (See  <a class="medical medical_review" href="/d/html/2909.html" rel="external">"Myophosphorylase deficiency (glycogen storage disease V, McArdle disease)"</a> and  <a class="medical medical_review" href="/d/html/2907.html" rel="external">"Phosphofructokinase deficiency (glycogen storage disease VII, Tarui disease)"</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>Enzyme replacement therapy for PGK deficiency is not available. Supportive care (eg, <a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">folic acid</a> supplementation), routine monitoring, and the role of splenectomy are discussed separately. (See  <a class="medical medical_review" href="/d/html/7128.html" rel="external">"Rare RBC enzyme disorders", section on 'General principles of management'</a> and  <a class="medical medical_review" href="/d/html/7128.html" rel="external">"Rare RBC enzyme disorders", section on 'Phosphoglycerate kinase (PGK) deficiency'</a>.)</p><p>Hematopoietic cell transplantation may be an option. Allogeneic bone marrow transplant for PGK deficiency was performed in a three-year-old child with hemolytic anemia and progressive neurologic involvement [<a href="#rid30">30</a>]. The patient continued to experience significant improvement four years posttransplant, with no hemolytic episodes and amelioration of his neurologic symptoms.</p><p class="headingAnchor" id="H6"><span class="h1">PHOSPHOGLYCERATE MUTASE DEFICIENCY</span><span class="headingEndMark"> — </span>PGAM catalyzes the conversion of 3-phosphoglycerate to 2-phosphoglycerate. Deficiency of the muscle isoform of the enzyme (PGAM2; MIM # 261670) results in muscle disease (glycogen storage disease [GSD] X) that becomes apparent in childhood or adolescence.</p><p class="headingAnchor" id="H7"><span class="h2">Genetics</span><span class="headingEndMark"> — </span>The muscle form of phosphoglycerate mutase (PGAM-M) maps to chromosome 7p13-p12.3 [<a href="#rid31">31</a>]. The gene for the brain subunit (PGAM-B) maps to chromosome 10q25 [<a href="#rid32">32,33</a>]. Human PGAM is a dimer consisting of different amounts of muscle (MM) isozyme, brain (BB) isozyme, and the intermediate hybrid (MB) isozyme.</p><p>Inheritance is autosomal recessive. Various distinct pathogenic variants have been described in studies of African American, African, and White patients with PGAM-M deficiency [<a href="#rid34">34-39</a>]. Symptomatic heterozygotes have been reported [<a href="#rid40">40,41</a>], as has an asymptomatic patient with a partial PGAM deficiency [<a href="#rid42">42</a>] and a late-onset case at the age of 44 years [<a href="#rid38">38</a>].</p><p class="headingAnchor" id="H8"><span class="h2">Clinical features</span><span class="headingEndMark"> — </span>PGAM deficiency presents primarily with dynamic symptoms, such as exercise intolerance, muscle aches, cramps, and myoglobinuria following intense physical activity [<a href="#rid5">5,43</a>]. Symptoms may begin in childhood or adolescence and mimic the manifestations of GSD V (muscle phosphorylase deficiency, McArdle disease). However, in contrast to patients with McArdle disease, a second-wind phenomenon does not occur, and infusion of lipid and lactate does not improve exercise capacity [<a href="#rid44">44</a>]. Between attacks, serum creatine kinase (CK) levels may be elevated.</p><p class="headingAnchor" id="H20307191"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>Muscle biopsy shows mild glycogen storage in most cases. Subsarcolemmal tubular aggregates have been detected in type 2 fibers in muscle biopsies from patients with PGAM deficiency [<a href="#rid34">34,42,45</a>]. Albeit nonspecific, this pathologic finding in a patient with exercise-induced cramps and recurrent myoglobinuria is highly suggestive of PGAM deficiency. PGAM-M activity is decreased on enzyme assay, and molecular analysis like targeted exome sequencing may reveal pathogenic variants in the <em>PGAM</em> gene [<a href="#rid46">46</a>].</p><p class="headingAnchor" id="H9"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>No effective therapy is available for PGAM deficiency. A single patient with PGAM deficiency became asymptomatic on <a class="drug drug_general" data-topicid="9322" href="/d/drug information/9322.html" rel="external">dantrolene</a> treatment and had a forearm ischemic test without exercise-induced contractures. This patient had tubular aggregates and increased Ca2+-adenosine triphosphatase (ATP) and calcium content in muscle tissue [<a href="#rid47">47</a>].</p><p class="headingAnchor" id="H1478362"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – Inborn errors of glycogen metabolism include the inherited glycogen storage diseases (GSDs)  (<a class="graphic graphic_table graphicRef54417" href="/d/graphic/54417.html" rel="external">table 1</a>). The major manifestations of disorders of glycogen metabolism affecting muscle are muscle cramps, exercise intolerance, easy fatigability, and progressive weakness. (See  <a class="medical medical_review" href="/d/html/2914.html" rel="external">"Other disorders of glycogen metabolism: GLUT2 deficiency and aldolase A deficiency", section on 'Introduction'</a> and  <a class="medical medical_review" href="/d/html/2941.html" rel="external">"Overview of inherited disorders of glucose and glycogen metabolism"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Phosphoglycerate kinase (PGK) deficiency</strong> – PGK deficiency can result in one of three distinct presentations or a variable combined presentation: central nervous system (CNS) dysfunction with seizures and intellectual disability that is associated with nonspherocytic hemolytic anemia; hereditary nonspherocytic hemolytic anemia without CNS involvement; isolated myopathy with exercise intolerance, myoglobinuria, cramps, and slowly progressive weakness; or all three findings. The diagnosis is confirmed by demonstrating a deficiency of PGK enzymatic activity in muscle biopsy tissue and/or erythrocytes or molecular analysis of the <em>PGK1</em> gene. Enzyme replacement therapy for PGK deficiency is not available. <a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">Folic acid</a> supplementation for hemolytic anemia is appropriate, along with monitoring for gallstones and for iron overload if frequent transfusions are needed. Hematopoietic cell transplantation may be an option. (See <a class="local">'Phosphoglycerate kinase deficiency'</a> above and  <a class="medical medical_review" href="/d/html/7128.html" rel="external">"Rare RBC enzyme disorders", section on 'General principles of management'</a> and  <a class="medical medical_review" href="/d/html/7128.html" rel="external">"Rare RBC enzyme disorders", section on 'Phosphoglycerate kinase (PGK) deficiency'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Phosphoglycerate mutase (PGAM) deficiency (GSD X)</strong> – PGAM deficiency (GSD X) presents primarily with dynamic symptoms, such as exercise intolerance, muscle aches, cramps, and myoglobinuria following intense physical activity. The diagnosis is confirmed by demonstrating a deficiency of PGAM-enzymatic activity in muscle biopsy tissue or molecular analysis of the <em>PGAM2</em> gene. (See <a class="local">'Phosphoglycerate mutase deficiency'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Meera Khan P, Westerveld A, Grzeschik KH, et al. X-linkage of human phosphoglycerate kinase confirmed in man-mouse and man-Chinese hamster somatic cell hybrids. Am J Hum Genet 1971; 23:614.</a></li><li><a class="nounderline abstract_t">Miwa S, Fujii H. Molecular basis of erythroenzymopathies associated with hereditary hemolytic anemia: tabulation of mutant enzymes. Am J Hematol 1996; 51:122.</a></li><li><a class="nounderline abstract_t">Spiegel R, Gomez EA, Akman HO, et al. Myopathic form of phosphoglycerate kinase (PGK) deficiency: a new case and pathogenic considerations. Neuromuscul Disord 2009; 19:207.</a></li><li><a class="nounderline abstract_t">Chiarelli LR, Morera SM, Bianchi P, et al. Molecular insights on pathogenic effects of mutations causing phosphoglycerate kinase deficiency. PLoS One 2012; 7:e32065.</a></li><li><a class="nounderline abstract_t">DiMauro S, Miranda AF, Khan S, et al. Human muscle phosphoglycerate mutase deficiency: newly discovered metabolic myopathy. Science 1981; 212:1277.</a></li><li><a class="nounderline abstract_t">Sugie H, Sugie Y, Nishida M, et al. Recurrent myoglobinuria in a child with mental retardation: phosphoglycerate kinase deficiency. J Child Neurol 1989; 4:95.</a></li><li><a class="nounderline abstract_t">Beutler E. PGK deficiency. Br J Haematol 2007; 136:3.</a></li><li><a class="nounderline abstract_t">Tamai M, Kawano T, Saito R, et al. Phosphoglycerate kinase deficiency due to a novel mutation (c. 1180A&gt;G) manifesting as chronic hemolytic anemia in a Japanese boy. Int J Hematol 2014; 100:393.</a></li><li><a class="nounderline abstract_t">Vissing J, Akman HO, Aasly J, et al. Level of residual enzyme activity modulates the phenotype in phosphoglycerate kinase deficiency. Neurology 2018; 91:e1077.</a></li><li><a class="nounderline abstract_t">Ramírez-Bajo MJ, Repiso A, la Ossa PP, et al. Enzymatic and metabolic characterization of the phosphoglycerate kinase deficiency associated with chronic hemolytic anemia caused by the PGK-Barcelona mutation. Blood Cells Mol Dis 2011; 46:206.</a></li><li><a class="nounderline abstract_t">Noel N, Flanagan JM, Ramirez Bajo MJ, et al. Two new phosphoglycerate kinase mutations associated with chronic haemolytic anaemia and neurological dysfunction in two patients from Spain. Br J Haematol 2006; 132:523.</a></li><li><a class="nounderline abstract_t">Flanagan JM, Rhodes M, Wilson M, Beutler E. The identification of a recurrent phosphoglycerate kinase mutation associated with chronic haemolytic anaemia and neurological dysfunction in a family from USA. Br J Haematol 2006; 134:233.</a></li><li><a class="nounderline abstract_t">Valentine WN, Hsieh HS, Paglia DE, et al. Hereditary hemolytic anemia associated with phosphoglycerate kinase deficiency in erythrocytes and leukocytes. A probable X-chromosome-linked syndrome. N Engl J Med 1969; 280:528.</a></li><li><a class="nounderline abstract_t">DiMauro S, Dalakas M, Miranda AF. Phosphoglycerate kinase deficiency: another cause of recurrent myoglobinuria. Ann Neurol 1983; 13:11.</a></li><li><a class="nounderline abstract_t">Shirakawa K, Takahashi Y, Miyajima H. Intronic mutation in the PGK1 gene may cause recurrent myoglobinuria by aberrant splicing. Neurology 2006; 66:925.</a></li><li><a class="nounderline abstract_t">Baba S, Kobayashi A, Yokoyama H, et al. Slowly progressive leukodystrophy in an adolescent male with phosphoglycerate kinase deficiency. Brain Dev 2018; 40:150.</a></li><li><a class="nounderline abstract_t">Rosa R, George C, Fardeau M, et al. A new case of phosphoglycerate kinase deficiency: PGK Creteil associated with rhabdomyolysis and lacking hemolytic anemia. Blood 1982; 60:84.</a></li><li><a class="nounderline abstract_t">Baba K, Fukuda T, Furuta M, et al. A Mild Clinical Phenotype with Myopathic and Hemolytic Forms of Phosphoglycerate Kinase Deficiency (PGK Osaka): A Case Report and Literature Review. Intern Med 2022; 61:3589.</a></li><li><a class="nounderline abstract_t">Morimoto A, Ueda I, Hirashima Y, et al. A novel missense mutation (1060G --&gt; C) in the phosphoglycerate kinase gene in a Japanese boy with chronic haemolytic anaemia, developmental delay and rhabdomyolysis. Br J Haematol 2003; 122:1009.</a></li><li><a class="nounderline abstract_t">Fermo E, Bianchi P, Chiarelli LR, et al. A new variant of phosphoglycerate kinase deficiency (p.I371K) with multiple tissue involvement: molecular and functional characterization. Mol Genet Metab 2012; 106:455.</a></li><li><a class="nounderline abstract_t">Sotiriou E, Greene P, Krishna S, et al. Myopathy and parkinsonism in phosphoglycerate kinase deficiency. Muscle Nerve 2010; 41:707.</a></li><li><a class="nounderline abstract_t">DiMauro S, Spiegel R. Progress and problems in muscle glycogenoses. Acta Myol 2011; 30:96.</a></li><li><a class="nounderline abstract_t">Sakaue S, Kasai T, Mizuta I, et al. Early-onset parkinsonism in a pedigree with phosphoglycerate kinase deficiency and a heterozygous carrier: do PGK-1 mutations contribute to vulnerability to parkinsonism? NPJ Parkinsons Dis 2017; 3:13.</a></li><li><a class="nounderline abstract_t">Morales-Briceño H, Ha AD, London K, et al. Parkinsonism in PGK1 deficiency implicates the glycolytic pathway in nigrostriatal dysfunction. Parkinsonism Relat Disord 2019; 64:319.</a></li><li class="breakAll">Akman HO, Oldfors A, DiMauro S. Glycogen storage diseases of muscle. In: Neuromuscular Disorders of Infancy, Childhood, and Adolescence: A Clinician's Approach, Darras BT, Jones HRJ, Ryan MM, et al (Eds), Academic Press, San Diego 2015. p.735.</li><li><a class="nounderline abstract_t">Gutierrez E, Bayes MG, Mallick J, et al. Recognition of a novel variant of phosphoglycerate kinase 1 deficiency PGK1 Galveston (c.472G &gt; C) in a child with hemolytic anemia, neurologic dysfunction and myopathy. Pediatr Hematol Oncol 2023; 40:76.</a></li><li class="breakAll">PGK1 full gene sequencing through Emory Genetics Laboratory: http://genetics.emory.edu/egl/tests/?testid=1481 (Accessed on December 13, 2011).</li><li><a class="nounderline abstract_t">Morava E, Wortmann SB, van Essen HZ, et al. Biochemical characteristics and increased tetraglucoside excretion in patients with phosphorylase kinase deficiency. J Inherit Metab Dis 2005; 28:703.</a></li><li><a class="nounderline abstract_t">Aasly J, van Diggelen OP, Boer AM, Brønstad G. Phosphoglycerate kinase deficiency in two brothers with McArdle-like clinical symptoms. Eur J Neurol 2000; 7:111.</a></li><li><a class="nounderline abstract_t">Rhodes M, Ashford L, Manes B, et al. Bone marrow transplantation in phosphoglycerate kinase (PGK) deficiency. Br J Haematol 2011; 152:500.</a></li><li><a class="nounderline abstract_t">Edwards YH, Sakoda S, Schon E, Povey S. The gene for human muscle-specific phosphoglycerate mutase, PGAM2, mapped to chromosome 7 by polymerase chain reaction. Genomics 1989; 5:948.</a></li><li><a class="nounderline abstract_t">Tsujino S, Sakoda S, Mizuno R, et al. Structure of the gene encoding the muscle-specific subunit of human phosphoglycerate mutase. J Biol Chem 1989; 264:15334.</a></li><li><a class="nounderline abstract_t">Junien C, Despoisse S, Turleau C, et al. Assignment of phosphoglycerate mutase (PGAMA) to human chromosome 10. Regional mapping of GOT1 and PGAMA to subbands 10q26.1 (or q25.3). Ann Genet 1982; 25:25.</a></li><li><a class="nounderline abstract_t">Naini A, Toscano A, Musumeci O, et al. Muscle phosphoglycerate mutase deficiency revisited. Arch Neurol 2009; 66:394.</a></li><li><a class="nounderline abstract_t">Tsujino S, Shanske S, Sakoda S, et al. The molecular genetic basis of muscle phosphoglycerate mutase (PGAM) deficiency. Am J Hum Genet 1993; 52:472.</a></li><li><a class="nounderline abstract_t">Tsujino S, Shanske S, Sakoda S, et al. Molecular genetic studies in muscle phosphoglycerate mutase (PGAM-M) deficiency. Muscle Nerve Suppl 1995; 3:S50.</a></li><li><a class="nounderline abstract_t">Toscano A, Tsujino S, Vita G, et al. Molecular basis of muscle phosphoglycerate mutase (PGAM-M) deficiency in the Italian kindred. Muscle Nerve 1996; 19:1134.</a></li><li><a class="nounderline abstract_t">Tonin P, Bruno C, Cassandrini D, et al. Unusual presentation of phosphoglycerate mutase deficiency due to two different mutations in PGAM-M gene. Neuromuscul Disord 2009; 19:776.</a></li><li><a class="nounderline abstract_t">Koo B, Oskarsson B. Phosphoglycerate mutase deficiency (glycogen storage disease X) caused by a novel variant in PGAM-M. Neuromuscul Disord 2016; 26:688.</a></li><li><a class="nounderline abstract_t">Hadjigeorgiou GM, Kawashima N, Bruno C, et al. Manifesting heterozygotes in a Japanese family with a novel mutation in the muscle-specific phosphoglycerate mutase (PGAM-M) gene. Neuromuscul Disord 1999; 9:399.</a></li><li><a class="nounderline abstract_t">Joshi PR, Knape M, Zierz S, Deschauer M. Phosphoglycerate mutase deficiency: case report of a manifesting heterozygote with a novel E154K mutation and very late onset. Acta Neuropathol 2009; 117:723.</a></li><li><a class="nounderline abstract_t">Salameh J, Goyal N, Choudry R, et al. Phosphoglycerate mutase deficiency with tubular aggregates in a patient from Panama. Muscle Nerve 2013; 47:138.</a></li><li><a class="nounderline abstract_t">Servidei S, DiMauro S. Disorders of glycogen metabolism of muscle. Neurol Clin 1989; 7:159.</a></li><li><a class="nounderline abstract_t">Vissing J, Quistorff B, Haller RG. Effect of fuels on exercise capacity in muscle phosphoglycerate mutase deficiency. Arch Neurol 2005; 62:1440.</a></li><li><a class="nounderline abstract_t">Oh SJ, Park KS, Ryan HF Jr, et al. Exercise-induced cramp, myoglobinuria, and tubular aggregates in phosphoglycerate mutase deficiency. Muscle Nerve 2006; 34:572.</a></li><li><a class="nounderline abstract_t">Nayab A, Alam Q, Alzahrani OR, et al. Targeted exome sequencing identified a novel frameshift variant in the PGAM2 gene causing glycogen storage disease type X. Eur J Med Genet 2021; 64:104283.</a></li><li><a class="nounderline abstract_t">Vissing J, Schmalbruch H, Haller RG, Clausen T. Muscle phosphoglycerate mutase deficiency with tubular aggregates: effect of dantrolene. Ann Neurol 1999; 46:274.</a></li></ol></div><div id="topicVersionRevision">Topic 2911 Version 16.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5132070" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : X-linkage of human phosphoglycerate kinase confirmed in man-mouse and man-Chinese hamster somatic cell hybrids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8579052" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Molecular basis of erythroenzymopathies associated with hereditary hemolytic anemia: tabulation of mutant enzymes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19157875" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Myopathic form of phosphoglycerate kinase (PGK) deficiency: a new case and pathogenic considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22348148" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Molecular insights on pathogenic effects of mutations causing phosphoglycerate kinase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6262916" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Human muscle phosphoglycerate mutase deficiency: newly discovered metabolic myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2715616" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Recurrent myoglobinuria in a child with mental retardation: phosphoglycerate kinase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17222195" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : PGK deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24934115" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Phosphoglycerate kinase deficiency due to a novel mutation (c. 1180A&gt;G) manifesting as chronic hemolytic anemia in a Japanese boy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30111548" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Level of residual enzyme activity modulates the phenotype in phosphoglycerate kinase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21269848" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Enzymatic and metabolic characterization of the phosphoglycerate kinase deficiency associated with chronic hemolytic anemia caused by the PGK-Barcelona mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16412025" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Two new phosphoglycerate kinase mutations associated with chronic haemolytic anaemia and neurological dysfunction in two patients from Spain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16740138" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The identification of a recurrent phosphoglycerate kinase mutation associated with chronic haemolytic anaemia and neurological dysfunction in a family from USA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5764452" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Hereditary hemolytic anemia associated with phosphoglycerate kinase deficiency in erythrocytes and leukocytes. A probable X-chromosome-linked syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6830158" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Phosphoglycerate kinase deficiency: another cause of recurrent myoglobinuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16567715" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Intronic mutation in the PGK1 gene may cause recurrent myoglobinuria by aberrant splicing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28801086" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Slowly progressive leukodystrophy in an adolescent male with phosphoglycerate kinase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7082849" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A new case of phosphoglycerate kinase deficiency: PGK Creteil associated with rhabdomyolysis and lacking hemolytic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35527021" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : A Mild Clinical Phenotype with Myopathic and Hemolytic Forms of Phosphoglycerate Kinase Deficiency (PGK Osaka): A Case Report and Literature Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12956773" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : A novel missense mutation (1060G --&gt;C) in the phosphoglycerate kinase gene in a Japanese boy with chronic haemolytic anaemia, developmental delay and rhabdomyolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22705348" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A new variant of phosphoglycerate kinase deficiency (p.I371K) with multiple tissue involvement: molecular and functional characterization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20151463" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Myopathy and parkinsonism in phosphoglycerate kinase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22106711" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Progress and problems in muscle glycogenoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28649613" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Early-onset parkinsonism in a pedigree with phosphoglycerate kinase deficiency and a heterozygous carrier: do PGK-1 mutations contribute to vulnerability to parkinsonism?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30975619" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Parkinsonism in PGK1 deficiency implicates the glycolytic pathway in nigrostriatal dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30975619" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Parkinsonism in PGK1 deficiency implicates the glycolytic pathway in nigrostriatal dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35608390" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Recognition of a novel variant of phosphoglycerate kinase 1 deficiency PGK1 Galveston (c.472G &gt; C) in a child with hemolytic anemia, neurologic dysfunction and myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35608390" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Recognition of a novel variant of phosphoglycerate kinase 1 deficiency PGK1 Galveston (c.472G &gt; C) in a child with hemolytic anemia, neurologic dysfunction and myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16151901" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Biochemical characteristics and increased tetraglucoside excretion in patients with phosphorylase kinase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10809925" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Phosphoglycerate kinase deficiency in two brothers with McArdle-like clinical symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21223252" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Bone marrow transplantation in phosphoglycerate kinase (PGK) deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2556344" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The gene for human muscle-specific phosphoglycerate mutase, PGAM2, mapped to chromosome 7 by polymerase chain reaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2549058" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Structure of the gene encoding the muscle-specific subunit of human phosphoglycerate mutase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6282177" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Assignment of phosphoglycerate mutase (PGAMA) to human chromosome 10. Regional mapping of GOT1 and PGAMA to subbands 10q26.1 (or q25.3).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19273759" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Muscle phosphoglycerate mutase deficiency revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8447317" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The molecular genetic basis of muscle phosphoglycerate mutase (PGAM) deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7603528" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Molecular genetic studies in muscle phosphoglycerate mutase (PGAM-M) deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8761269" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Molecular basis of muscle phosphoglycerate mutase (PGAM-M) deficiency in the Italian kindred.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19783439" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Unusual presentation of phosphoglycerate mutase deficiency due to two different mutations in PGAM-M gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27612597" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Phosphoglycerate mutase deficiency (glycogen storage disease X) caused by a novel variant in PGAM-M.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10545043" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Manifesting heterozygotes in a Japanese family with a novel mutation in the muscle-specific phosphoglycerate mutase (PGAM-M) gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19322572" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Phosphoglycerate mutase deficiency: case report of a manifesting heterozygote with a novel E154K mutation and very late onset.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23169535" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Phosphoglycerate mutase deficiency with tubular aggregates in a patient from Panama.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2646520" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Disorders of glycogen metabolism of muscle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16157752" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Effect of fuels on exercise capacity in muscle phosphoglycerate mutase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16881065" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Exercise-induced cramp, myoglobinuria, and tubular aggregates in phosphoglycerate mutase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34237446" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Targeted exome sequencing identified a novel frameshift variant in the PGAM2 gene causing glycogen storage disease type X.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10443898" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Muscle phosphoglycerate mutase deficiency with tubular aggregates: effect of dantrolene.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
